VIVANET, GRAZIA

VIVANET, GRAZIA  

Universita' degli Studi di MILANO  

Mostra records
Risultati 1 - 8 di 8 (tempo di esecuzione: 0.0 secondi).
Titolo Data di pubblicazione Autori Tipo File Abstract
A set of easy and stringent criteria to identify immune-related adverse events (IrAE Scoring System, ISS) improves correlation with outcome in a phase 1-2 trial population 2022 Mazzarella, LGiugliano, FNicolo', ECrimini, EUliano, JCorti, CRepetto, MAntonarelli, GAscione, LVivanet, GCriscitiello, CCurigliano, G + Article (author) -
COVID-19 related risk in patients enrolled in early-phase clinical trials 2021 Morganti, SCorti, CVivanet, GCrimini, EAntonarelli, GCurigliano, G + Article (author) -
Evolution of low HER2 expression between early and advanced-stage breast cancer 2022 Giugliano F.Zagami P.Vivanet G.Bellerba F.Trapani D.Criscitiello C.Curigliano G. + Article (author) -
High-dose continuous-infusion ifosfamide in advanced thymic epithelial Tumors: A TYME network study 2023 Conforti, FabioVivanet, GraziaCorti, ChiaraCurigliano, Giuseppe + Article (author) -
High-Dose Ifosfamide for advanced thymic epithelial tumors (TETs): a TYME network study 2022 Vivanet GCorti CCatania CCurigliano G + Article (author) -
Immune-related adverse events are correlated with significantly improved outcome in a phase I trial population exposed to combination immunotherapy 2021 Giugliano, FCrimini, EUliano, JCorti, CRepetto, MAntonarelli, GVivanet, GCriscitiello, CCurigliano, G + Article (author) -
Safety of covid-19 mrna vaccines in patients with cancer enrolled in early-phase clinical trials 2021 Trillo Aliaga P.Trapani D.Crimini E.Antonarelli G.Vivanet G.Morganti S.Corti C.Criscitiello C.Curigliano G. + Article (author) -
SARS-CoV-2 vaccine in patients with thymic epithelial tumours with and without active or pre-existing autoimmune disorders: Brief report of a TYME network safety analysis 2022 Giugliano, FedericaGalli, GiuliaCorti, ChiaraUliano, JacopoVivanet, GraziaCurigliano, GiuseppeConforti, Fabio + Article (author) -